Dalbavancin (BI 397) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC₉₀s of 0.06 μg/mL and 0.25 μg/mL, respectively^[1][2]. IC50 & Target: MIC90: 0.06 μg/mL (Staphylococcus aureus) and 0.25 μg/mL (Bacillus anthracis)^[1][2] In Vitro: Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci, organisms against which it has shown greater potency than existing glycopeptide therapeutic agents^[1][2]. In Vivo: Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens^[1].